Unsymmetrical cyclic diamine compound

A pharmaceutical composition comprising, as an active ingredient, a cyclic diamine compound of formula (1):

• wherein
• A is (CH2)n, (CH2)n—CH═CH, CO—(CH2)n or CO—(CH2)n—CH═CH, in which n is a number of 0 to 3;
• Z represents a formula (2) or (3):
• in which R1, R2, R4, R5 and R6 are individually a hydrogen atom, alkyl group, alkoxy group, halogen atom or nitro group;
• R3 is a hydrogen atom, alkyl group, alkoxy group, halogen atom, nitro group, naphthyl group, or phenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl groups, alkoxy groups, halogen atoms, a nitro group and a phenyl group;
• and X and Y are individually CH or a nitrogen atom;
• and m is 1 or 2;
• an acid-addition salt thereof, or a hydrate thereof.

A method for treating a disease caused by cell adhesion and/or cell infiltration, which comprises administering to a patient in need thereof an effective amount of a cyclic diamine compound of formula (1):

• wherein
• A is (CH2)n, (CH2)n—CH═CH, CO—(CH2)n or CO—(CH2)n—CH═CH, in which n is a number of of 0 to 3;
• Z represents a formula (2) or (3):
• in which R1, R2, R4, R5 and R6 are individually a hydrogen atom, alkyl group, alkoxy group, halogen atom or nitro group;
• R3 is a hydrogen atom, alkyl group, alkoxy group, halogen atom, nitro group, naphthyl group, or phenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of alkyl groups, alkoxy groups, halogen atoms, a nitro group and a phenyl group;
• and X and Y are individually CH or a nitrogen atom;
• and m is 1 or 2;
• an acid-addition salt thereof, or a hydrate thereof.